Research Highlights Critical Gaps in GLP-1 Receptor Agonist Studies for Women, Despite Predominant Usage
A new series of papers presented at the European Association for the Study of Diabetes (EASD) and published in The Lancet Obstetrics, Gynaecology & Women's Health reveals significant research gaps concerning the use of GLP-1 receptor agonists (GLP-1 RAs) in women, despite women being the predominant users of these medications. The research indicates that GLP-1 RAs lead to greater weight loss in women than men, with comparable glycemic benefits. However, real-world data shows women report a higher frequency of adverse effects, including headache, vomiting, and dizziness, compared to men. Critical evidence gaps persist in areas such as reproductive safety, mental health, menopause, and long-term body composition for women using these drugs. The authors, including Professor Paul Franks and Professor Claire Meek, are calling for extensive research across various domains, emphasizing the need for sex- and ethnicity-stratified trials and equitable access to GLP-1 RAs globally, particularly in low- and middle-inc...